Objective: A meta-analysis of the studies involving Sacubitril/Valsartan in chronic heart
failure was performed to compare the efficacy and safety of Sacubitril/Valsartan with …

Abstract Background and Objective Sacubitril/valsartan improved the prognosis of patients
with heart failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the …

Aim: The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range
ejection fractions (HFmrEF) remains unclear. This study aimed to investigate the effects of …

The role of sacubitril and/or valsartan in patient with heart failure (HF) is established.
Whether sacubitril and/or valsartan plays a role in improving outcomes in patients after ST …

Background The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan is known to
improve outcomes of cardiac death and hospitalization due to heart failure in patients with …

Aims Although the beneficial effect of sacubitril/valsartan (SAC/VAL) compared to enalapril
was consistent across ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy …

Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has
become a milestone in the treatment of patients with chronic heart failure (HF) with reduced …

Heart failure is a term used to define a constellation of symptoms and signs that are
commonly attributed to the inability of the heart to produce a cardiac output that meets the …

Objective: The current meta-analysis reviews the different randomized controlled trials
(RCTs) on the use of sacubitril-valsartan (SV) thoroughly and assesses its effectiveness and …

The aim of this study was to assess whether angiotensin receptor/neprilysin inhibitor (ARNI)
decreases ventricular arrhythmic burden compared to angiotensin-converting enzyme …